These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11418525)

  • 1. The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice.
    Yoshizumi S; Takahashi Y; Murata M; Domon H; Furuya N; Ishii Y; Matsumoto T; Ohno A; Tateda K; Miyazaki S; Yamaguchi K
    J Antimicrob Chemother; 2001 Jul; 48(1):137-40. PubMed ID: 11418525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
    Yoshizumi S; Domon H; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Apr; 42(4):785-8. PubMed ID: 9559783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
    Higa F; Arakaki N; Tateyama M; Koide M; Shinzato T; Kawakami K; Saito A
    J Antimicrob Chemother; 2003 Dec; 52(6):920-4. PubMed ID: 14613952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.
    Naber KG; di Silverio F; Geddes A; Guibert J
    J Antimicrob Chemother; 1996 May; 37 Suppl A():135-44. PubMed ID: 8737133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
    Niki Y; Miyashita N; Kubota Y; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Apr; 41(4):857-9. PubMed ID: 9087506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones: how to use (but not overuse) these antibiotics.
    Sable CA; Scheld WM
    Geriatrics; 1993 Jun; 48(6):41-4, 49-51. PubMed ID: 8500773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary tract infections: risk factors and therapeutic trends].
    Margariti PA; Astorri AL; Mastromarino C
    Recenti Prog Med; 1997 Feb; 88(2):65-8. PubMed ID: 9148368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection in the elderly: studies with lomefloxacin.
    Crome P; Bruce-Jones P
    Am J Med; 1992 Apr; 92(4A):126S-129S. PubMed ID: 1316062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temafloxacin vs ciprofloxacin for UTI.
    Ganiats TG; Norcross WA
    J Fam Pract; 1992 Jul; 35(1):14, 16, 18. PubMed ID: 1319461
    [No Abstract]   [Full Text] [Related]  

  • 16. Laboratory and clinical study of balofloxacin (Q-35), a new fluoroquinolone, in urinary tract infection.
    Suzuki K; Horiba M; Ishikawa K; Katoh S; Naide Y; Yanaoka M; Andoh S
    Drugs; 1995; 49 Suppl 2():376-8. PubMed ID: 8549367
    [No Abstract]   [Full Text] [Related]  

  • 17. Temafloxacin vs ciprofloxacin for UTI.
    Hornstein LE
    J Fam Pract; 1992 Jul; 35(1):14; author reply 18. PubMed ID: 1319460
    [No Abstract]   [Full Text] [Related]  

  • 18. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temafloxacin: an overview.
    Pankey GA
    Am J Med; 1991 Dec; 91(6A):166S-172S. PubMed ID: 1662889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Maxaquin and ciprofloxacin in the treatment of complicated and recurrent urinary infections in adults].
    Savitskaia KI; Trapeznikova MF; Nekhorosheva AG; Solodilova OE; Nasonov VN; Dutov VV; Kalinin VN; Shanina AG; Rusanova EV
    Klin Med (Mosk); 1994; 72(2):38-42. PubMed ID: 8015241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.